EC
CCCC icon

EntryPoint Capital’s C4 Therapeutics CCCC Stock Holding History

EntryPoint Capital’s Portfolio CCCC Stock Details CCCC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-458
Closed -$2.12K – 694
2024
Q2 		$2.12K Sell
458
-28,058
-98% -$167K ﹤0.01% 807
2024
Q1 		$233K Buy
+28,516
New +$221K 0.21% 68

Other funds holding CCCC

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

EntryPoint Capital's CCCC Position: Q3 2024 in Review

EntryPoint Capital sold out of C4 Therapeutics (CCCC) in Q3 2024, closing a stake of 458 shares — an estimated $2.12K sold.

EntryPoint Capital first reported a position in CCCC in Q1 2024 and held it in 2 quarters. The position peaked at $233K in Q1 2024. 118 funds tracked by Wall St. Rank hold CCCC as of Q3 2024.

  • EntryPoint Capital reported no remaining C4 Therapeutics position as of Q3 2024 after selling out during the quarter.
  • EntryPoint Capital sold 458 C4 Therapeutics shares in Q3 2024, an estimated $2.12K.
  • EntryPoint Capital first reported a position in C4 Therapeutics in Q1 2024 and held it in 2 quarters.
  • EntryPoint Capital's C4 Therapeutics position peaked at $233K in Q1 2024.
  • 118 funds tracked by Wall St. Rank held C4 Therapeutics as of Q3 2024.

Based on EntryPoint Capital's 13F filing for Q3 2024, filed 13 Nov 2024.